论文部分内容阅读
在斯里兰卡康提地区,对3月龄、18月龄、5～7岁和9～11岁4个年龄组共740名于出生后第1个月接种过卡介苗的健康儿童进行了曼托试验。此外对来自同学校的61名在10岁时复种过卡介苗的儿童于复种后3个月也进行此项试验。皮试用1个结核菌素单位纯蛋白衍生物(PPD)RT23(含吐温80),方法系标准皮内曼托技术。试验部位为左前臂掌侧中三分之一处。72小时后测量硬结大小。为了尽量减少假阴性反应,本试验排除了患有感染性疾病、用皮质类固醇或免疫抑制剂治疗以及在过去6个月内患过麻疹的儿童,并避免同时接种其他活疫苗。作者还对90例经细菌学证实为结核病患儿作了曼托试验,作为对照。此外,还观察了卡介苗接种
In the Kandy region of Sri Lanka, a total of 740 healthy children aged 3 months, 18 months, 5 to 7 years, and 9 to 11 years of age in four age groups were immunized with BCG at the first month of life for the Manto test. In addition, 61 children from the same school who had been given BCG at 10 years of age were also tested at 3 months after the second vaccination. Skin test 1 tuberculin unit of pure protein derivative (PPD) RT23 (containing Tween 80), the method standard Pineda Manto technology. The test site is one-third of the left forearm’s palmar side. The size of the induration was measured 72 hours later. In order to minimize false-negative reactions, this study excluded children with infectious diseases, those treated with corticosteroids or immunosuppressive agents and those who had had measles within the past 6 months and avoided the simultaneous vaccination of other live vaccines. The authors also Mantuo test of 90 cases of bacteriologically confirmed tuberculosis as a control. In addition, BCG vaccination was also observed